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Zika and the Regulatory Regime for Licensing
Vaccines for Use During Pregnancy
Sam Halabi *
I. INTRODUCTION
Microcephaly and other severe fetal brain defects (congenital Zika
syndrome) caused by the Zika virus have prompted an urgent effort to
develop and license a safe and efficacious vaccine.' Yet, that effort has run
up against one of the most formidable barriers in vaccine research: pregnant
women are almost always excluded from clinical trials for fear that the
intervention may harm the fetus.2  This article analyzes the existing
regulatory framework for vaccines intended for use during pregnancy in an
effort to identify ways the process may be reconsidered in light of recent
public health emergencies that had a disproportionate effect on pregnant
women.
Despite those recent public health emergencies and the routine
administration of immunizations like diphtheria, pertussis, and tetanus to
pregnant women, there is no vaccine licensed for use during pregnancy in the
United States.3 The regulatory review normally required by the U.S. Food
and Drug Administration ("FDA") for new drugs and biologic products
(including vaccines) demands substantial evidence as to safety, purity, and
potency both generally and for subpopulations designated on a product's
label. However, vaccines routinely administered during pregnancy are
permitted through an alternative post hoc system that does not rely on the
gold standard of double-blind, placebo controlled trials.' Under that
alternative, the FDA defers to the U.S. Centers for Disease Control and
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1. Erika Check Hayden, The Race is on to Develop Zika Vaccine, NATURE (March 28,
2016), http://www.nature.com/news/the-race-is-on-to-develop-zika-vaccine-1.19634.
2. Mary C. Blehar et al., Enrolling Pregnant Women: Issues in Clinical Research, 23
WOMEN'S HEALTH ISSUES e3 9, e40 (2013).
3. Getta K. Swamy & R. Phillips Heine, Vaccinations for Pregnant Women, OBSTETRICS
& GYNECOLOGY 1, 10 (2015).
4. Jeffery N. Roberts & Marion F. Gruber, Regulatory Considerations in the Clinical
Development of Vaccines Indicated for Use During Pregnancy, 33 VACCINE 966, 967 (2015).
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Prevention's Advisory Committee for Immunization Practices ("ACIP"), the
World Health Organization's Strategic Advisory Group of Experts on
Immunization, and other national immunization technical advisory groups.'
Where those organizations recommend specific immunizations for pregnant
women, the FDA does not consider the use inconsistent with the product's
labeling or "off-label".6
This article situates the Zika threat in the context of the regulatory
approval process for vaccines intended for use during pregnancy. In doing
so, it suggests that the discrepancy between the review process overseen by
the FDA and the alternative (but prevailing) process managed by national
immunization technical advisory groups (ACIP, physician organizations,
etc.) must be resolved as emerging viral threats pose specialized risks to
pregnant women and their unborn children.
Part II provides a brief history of Zika and its emergence as a viral threat
uniquely dangerous to pregnant women. Part III explains the regulatory
complexities surrounding the licensing of vaccines intended for pregnancy.
Lastly, part IV analyzes the disruptions the current regulatory system causes
to the research, development, and approval process for vaccines intended for
pregnant women.
II. THE ZIKA THREAT
A. The Zika Disease Profile
The Zika virus is a flavivirus related to yellow fever, dengue, West Nile,
and Japanese encephalitis viruses. 7 It was discovered in Uganda in 1947
during the course of mosquito and primate surveillance.' The virus has
historically circulated in wild primates and arboreal mosquitoes and rarely
caused "recognized spillover" infections in humans. 9 However, between
2008 and 2016, both the number of geographic locations affected by Zika and
the prevalence in those locations have increased, showing the worldwide
spread of the virus.'o By 2008, the virus had affected populations
5. The Advisory Conunittee on Immunization Practices (ACIP), Questions andAnswers,
ACIP, https://www.cdc.gov/vaccines/hcp/conversations/downloads/vacsafe-acip-color-
office.pdf pdf (last reviewed Apr. 15, 2016).
6. Roberts & Gruber, supra note 4, at 966-67.
7. Edward B. Hayes, Zika Virus Outside Africa, 15 EMERGING INFECTIOUS DISEASES
1347, 1347 (2009).
8. G.W.A. Dick, S.F. Kitchen & A.J. Haddow, Zika Virus (I). Isolations and Serological
Specificity, 46 TRANSACTIONS ROYAL Soc'Y TROPICAL MED. & HYGIENE 509, 509-11 (1952).
9. Anthony S. Fauci & David M. Morens, Zika Virus in the Americas - Yet Another
Arbovirus Threat, 374 NEWENG. J. MED. 601, 601 (2016).
10. Charleen McNeill et al., Zika: What Providers Need to Know, 12 J. NURSE PRAC. 359,
360 (2016).
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sporadically in Africa and Asia for half a century." Now, more than 60
countries and territories have continuing transmission of the disease.1 2
Zika is spread mostly by the bite of infected Aedes species mosquitoes,
which primarily bite during the day, late afternoon, and early evening.1
Rapid spread is nearly "guaranteed" in areas that have large mosquito
populations." Although mosquitoes are the primary mode of transporting
Zika, it can also be transmitted via sexual intercourse." Zika RNA has been
detected in other body fluids like saliva, semen, and amniotic fluid.'6
For most people, complications from infection with the Zika virus do not
result in hospitalization or serious illness." However, complications may be
more senous in pregnant women and their newborn children.'" Zika may be
passed from a pregnant woman to her fetus.' 9 The most common
complications known are microcephaly in infants born to women who had
Zika symptoms, pregnancy loss, ocular lesions, and temporary hearing loss. 2 0
Historically, Zika virus infections caused symptoms like fever, muscle aches,
eye pain, prostration, and maculopapular rash. 2 1 These ". . . . symptoms are
usually mild and last for 2 to 7 days," and may go unrecognizable or be
misdiagnosed as dengue, chikungunya, or other viral infections that manifest
with fever and rashes. 22 The Zika virus is also associated with Guillain-Barre
syndrome. 23  Guillain-Barre syndrome is a disorder in which the body's
immune system attacks part of the peripheral nervous system and results in
symptoms such as weakness, tingling sensations in the legs, and in some life-
11. Martin Enserink, An Obscure Mosquito-Borne Disease goes Global, 350 Sci. MAG.
1012, 1012 (Nov. 27, 2015),
https://www.cvnbs.colostate.edu/mip/newsletter/images/Science-2015-Enserink- 1012-
3%20(1).pdf.
12. Michelle Roberts, Zika Vaccine 'Works Very Well' in Mice, BBC NEWS (June 28,
2016), http://www.bbc.com/news/health-36645822.
13. Rapid Risk Assessment: Zika Virus Epidemic in the Americas: Potential Association
with Microcephaly and Guillain-Barrd Syndrome, EUR. CTR. FOR DISEASE CONT. 9 (Dec. 10,
2015), http://ecdc.europa.eu/en/publications/Publications/zika-virus-americas-association-
with-microcephaly-rapid-risk-assessment.pdf [hereinafter RapidRiskAssessment].
14. Enserink, supra note 11, at 1012.
15. McNeill et al, supra note 10, at 360.
16. Id.
17. Id.
18. Id (The 2 most common complications known to date are microcephaly in infants
born to pregnant women who had ZIKV symptoms during pregnancy and Guillain-Barr6
syndrome in adults).
19. About Zika: What We Know, CTR. FOR DISEASE CONT.,
http://www.cdc.gov/zika/about/index.htmil (last updated Sep. 29, 2016).
20. McNeill et al., supra note 10, at 360.
21. Fauci & Morens, supra note 9, at 602.
22. Rapid Risk Assessment, supra note 13, at 2.
23. Guillain-Barrd Syndrome Fact Sheet, NAT'L INST. NEUROLOGICAL DISORDERS &
STROKE (July 2011), http://www.ninds.nih.gov/disorders/gbs/detail gbs.htm.
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threatening cases, the disease may affect breathing, blood pressure, or heart
rate.24
Zika infects populations at high rates. A 2009 study based on antibody
surveys estimated that an "astonishing" 73% of the population had become
infected with Zika virus during the big outbreak in Yap, an island group in
the Western Pacific that is part of the Federated States of Micronesia. 25 "Over
60% of the United States population live in areas conducive to seasonal
[Zika] transmission," and even some that live in areas where yearlong Zika
transmission is possible.2 6 As of January 18, 2017, the Centers for Disease
Control and Prevention ("CDC") reported 217 locally acquired mosquito-
borne cases of the Zika virus, and 4,682 travel-associated cases.2 7
B. The Scramble for a Vaccine
Because of the devastating potential of Zika, public health authorities,
academic researchers and vaccine manufacturers are in a race to develop a
safe and effective vaccine that will protect against the disease. 28  While
vaccines often take ten to fifteen years to develop, recent public health
emergencies have demonstrated that political will and financial incentives
may accelerate that time frame .29 An HiN1 vaccine was developed within
four months of the discovery of a new pandemic strain of the virus.30 An
Ebola vaccine developed through a complex research and development
network involving the Public Health Agency of Canada, NewLink Genetics,
Merck, and IDT Biologika, showed 100 percent effectiveness after the
development process accelerated with the West Africa epidemic that
24. Id.
25. Enserink, supra note 11, at 1012.
26. McNeill et al., supra note 10, at 360.
27. Case Counts in the United States, CTR. FOR DISEASE CONT.,
https://www.cdc.gov/zika/geo/united-states.html (last updated Jan. 19, 2017).
28. Katie Thomas, The Race for a Zika Vaccine, N.Y. TIMEs (Nov. 19, 2016),
http://www.nytimes.con2016/11/20/business/testing-the-liniits-of-biotech-in-the-race-for-a-
zika-vaccine.html?_r=0 ("Similar meetings were occurring elsewhere in the vaccine world -
at small companies like Inovio Pharmaceuticals and NewLink, in the offices of big
manufacturers like GlaxoSmithKline and Sanofi, and at the Walter Reed Army Institute of
Research, which is a few miles from the N.I.H. campus . . ."); Phase 2 Zika Vaccine Trial
Begins in U.S., Central and South America, NAT'L INST. OF HEALTH (Mar. 31, 2017),
https://www.nih.gov/news-events/news-releases/phase-2-zika-vaccine-trial-begins-us-
central-south-america.
29. Vaccine Development, Testing, and Regulation, HIST. VACCINES,
http://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-
regulation (last updated Jan. 27, 2016); Thomas, supra note 28 (demonstrating the political
and financial incentive of accelerating vaccine development in times of public health
emergencies).
30. Zakariya Al-Muharrmi, Understanding the Influenza A HIN] 2009 Pandemic, 10 QU
MED. J. 187, 187 (2010).
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unfolded between 2014 and 2016.31
What has not changed, despite the unique threat Zika poses to pregnant
women, is the exclusion of pregnant women during the potential vaccine's
research and development process.32 Even though Congress, in 1974, added
specific requirements for undertaking research involving pregnant women
(thus implicitly authorizing such research), vaccine and other medical
therapy developers have rarely engaged in that kind of research.33 The
discussion below outlines approval recommendations to the FDA for
vaccines intended for use during pregnancy and the alternative regulatory
channels that actually authorize such use.
III. THE REGULATORY PATHWAY(S) FOR VACCINES INTENDED FOR USE
DURING PREGNANCY
A. The FDA Approval Process
The Food and Drug Administration's Center for Biologics Evaluation and
Research ("CBER") is responsible for regulating vaccines in the United
States. CBER's approval facilitates the use of vaccines in countries that lack
regulatory capacity.34 Although clinical vaccine development follows the
same general pathway as for drugs and other biologics, the process in place
for vaccines intended for use during pregnancy, is not used.35
1. All Vaccines
As researchers understand and isolate the Zika virus, they seek to map, to
the greatest extent possible, the biological mechanism or mechanisms that
lead to disease.36 While some candidate vaccines occur naturally, most
31. Ana Maria Henao-Restrepo et al., Efficacy and Effectiveness of an rVSV-vectored
Vaccine in Preventing Ebola Virus Disease: Final Results from the Guinea Ring Vaccination,
Open-Label, Cluster-Randomised Trial, 389 THE LANCET 505, 511 (2017).
32. Saad B. Omer & Richard H. Beigi, Pregnancy in the Time of Zika: Addressing
Barriers for Developing Vaccines and Other Measures for Pregnant Women, 3 15 JAMA
1227, 1227 (2016).
33. Blehar et al., supra note 2, at e40.
34. Vaccine Product Approval Process, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/biologicsbloodvaccines/developmentapprovalprocess/biologicslicenseap
plicationsblaprocess/ucml33096.htm (last updated Aug. 24, 2015); U.S. FOOD & DRUG
ADMIN., CBER INTERIM STRATEGIC PLAN FY 2017-2019 9 (2017),
http://www.fda.gov/downloads/aboutfda/centersoffices/cber/ucm266867.pdf.
35. Vaccine Product Approval Process, supra note 34; Omer & Beigi, supra note 32, at
1227.
36. EDUARDO A. GROISMAN, PRINCIPLES OF BACTERIAL PATHOGENESIS 134 (2001)
("Essential to the establishment of a complete understanding of the host-pathogen interactions
that are necessary for the manifestation of disease is the identification and detailed
characterization of virulence factors produced by pathogens at each stage of the infection
24 Vol. 26
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candidates are developed using empirical approaches, historically running
the pathogen through a medium that substantially reduces its pathogenicity,
or killing or dissecting the virus after cultivation and using it with adjuvants,
or in multiple doses to prompt immune response.3 7 More recent approaches
like "reverse vaccinology" start from genomic sequences and, by computer
simulation, predict those antigens that are most likely to be vaccine
candidates.38 Vaccine candidates are then tested in animals after developing
models for immunogenicity and safety.39
After animal testing, a Zika vaccine sponsor would apply for
Investigational New Drug ("IND") status from the FDA which authorizes the
sponsor to undertake clinical trials on humans for safety, efficacy, and,
licensure. Phase I trials are designed to assess the safety, immunogenicity
and dose-response of the vaccine in, typically, 20-100 healthy volunteers.40
The IND application describes the vaccine, its method of manufacture and
quality control tests for release, information about the vaccine's safety and
ability to prompt a protective immune response in animal testing, and the
proposed clinical studies protocol.
Phase II studies involve several hundred healthy volunteers and
investigators focus on safety as well as immunogenicity.4 2 Phase II studies
focus on dose-ranges and vaccine components.43 Phase III vaccine trials
enroll up to thousands or tens of thousands of human subjects in order to
detect sometimes rare adverse events. In 1998, for example, a rotavirus
vaccine was licensed for use in the United States after phase III trials on
approximately 10,000 infants showed safety and efficacy.45 However, when
administered to a larger population, physicians and researchers observed an
association between the vaccine and bowel obstruction. 6 If larger phase III
studies confirm safety and efficacy, the vaccine is approved for marketing
after additional review of study data.
process.").
37. Rino Rappuoli, Reverse Vaccinology, a Genome-Based Approach to Vaccine
Development, 19 VACCINE 2688, 2689 (2001) (illustrating conventional vaccine development
in Figure 1).
38. Id. at 2690.
39. Id. (including animal models as an essential feature of reverse vaccinology).
40. See FDA IND Content & Format Rule, 21 C.F.R. § 312.23 (2017).
41. Vaccine Product Approval Process, supra note 34.
42. Id.
43. Id.
44. Id.
45. See L. Simonsen et al., More on RotaShield and Intussusception: The Role ofAge at
the Time of Vaccination, 192 J. INFECTIOUS DISEASES S36, S36 (2005).
46. Id.
47. NIH, FAQ - Clinical Trial Phases, U.S. NAT'L LIBRARY OF MED. (Jan. 1, 2001),
https://www.nlm.nih.gov/services/ctphases.html#top (last updated Apr. 18, 2008).
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2. Requirements for Vaccines Intended for Use During Pregnancy
Additional requirements apply to vaccines developed for use during
pregnancy. Animal testing and clinical testing must be specified to address
the potential reproductive risk of the product before pregnant women
participate in clinical trials." Phase I clinical trials must begin with non-
pregnant women of childbearing age.49 If results of the proposed vaccination
are positive, studies of the vaccine may be advanced into early studies of
pregnant women classified as low-risk (healthy mothers who experience few
or no complications)."o If adequate data from phase I clinical trials of
pregnant women is observed, phase II may begin to identify a pilot evaluation
of efficacy (i.e. a test to examine the feasibility of an approach that is intended
to be used in a larger scale study)." Phase III trials for vaccine candidates
intended for use during pregnancy use a randomized, blinded, well-controlled
study, wherein the control arm receives placebo and the primary endpoint is
prevention of clinical disease in a larger population of pregnant women.5 2
After clinical development stages, the vaccination would advance to the
licensing application where FDA reviewers would evaluate the information
necessary for a risk/benefit analysis and issue a recommendation regarding
approval of the vaccine.53
Evaluations of safety are crucial during each phase of clinic trials, and
continue after the approval of the vaccine.14 Until a vaccine is given to the
general population, all potential adverse reactions are unknown." Thus,
many vaccines are subjected to post-marketing surveillance, known as
"Phase IV" studies once on the market. 6 A key criterion during phase IV
studies is to determine if there is a "reasonable possibility that the drug (or
biologic) caused the event and whether the event (or a pattern of events) is
unexpected."" During general population use of the vaccine, it may be
necessary to develop a pregnancy registry, in order to explore potential
48. See Roberts & Gruber, supra note 4, at 968.
49. Id.
50. Id.
51. Id.
52. See Roberts & Gruber, supra note 4, at 968.
53. 42 U.S.C.A. § 262 (k) (2015); see also Vaccine Product Approval Process, supra
note 41.
54. See Roberts & Gruber, supra note 4, at 967; see also Alberto E. Tozzi et al.,
Assessment of Causality of Individual Adverse Events Following Immunization (AEFI): A
WHO Tool for Global Use, 31 VACCINE 5041, 5043 (2013),
http://www.sciencedirect.com/science/article/pii/S0264410X13011997.
55. See Vaccine Product Approval Process, supra note 34.
56. Id.
57. See Roberts & Gruber, supra note 4, at 969.
26 Vol. 26
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changes and improve the quality and utility of the vaccination."
3. Labeling
Vaccine approval also requires appropriate product labeling to inform
health care providers about the vaccine's proper use, including its benefits
and risks, to communicate with patients and parents, and to safely deliver the
vaccine.59 A product's package insert, also known as the "label," is a critical
element of the evaluation of a vaccination."o Vaccine labels must include a
section for usage during pregnancy.'
The FDA recently revised the regulations for the characterization of a drug
or biologic as it affects pregnancy and issued the Pregnancy and Lactation
Labeling Rule ("PLLR").62 The PLLR changed the labeling rule for
pharmaceuticals from categorizing risks into lettered categories (A, B, C, D,
and X) to providing a narrative summary of the risks of using the drug or
biologic during pregnancy. 6 3  Under the old system, Category A
pharmaceuticals were those, like folic acid supplements, where adequate and
well-controlled studies did not demonstrate a risk to the fetus in the first
trimester of pregnancy.6 1 Category B pharmaceuticals meant that there were
no adequate and well-controlled studies in pregnant women and animal data
were reassuring while Category C pharmaceuticals meant that there were no
adequate and well-controlled studies in pregnant women and also no animal
data. 5 Categories D and X conveyed fetal risk in investigational or
marketing studies.66
The new rule not only requires that this information be adapted to be given
in narrative form, but also that the labeling include clinical information to
help healthcare providers make prescribing decisions and counsel women
about the use of drugs during pregnancy.67
B. Alternative Regulatory Channels for Vaccines Intended for Use
During Pregnancy
Despite FDA guidance on approval of vaccines through these channels,
58. Id.
59. See Vaccine Product Approval Process, supra note 34.
60. See 21 C.F.R. §§ 201.56-57 (2015).
61. Id.
62. 21 C.F.R. § 201.57 (2015).
63. Marion F. Gruber, The US FDA Pregnancy Lactation and Labeling Rule -
Implications for Maternal Immunization, 33 VACCINE 6499, 6450 (2015).
64. Id.
65. Id.
66. Id.
67. Gruber, supra note 63, at 6500.
2017 27
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the system is unused. Instead, the approval for these vaccines is functionally
given to national technical advisory groups like ACIP, a statutory body
established to "develop recommendations on the use of vaccines in the
civilian population of the United States."6 ' ACIP reports to the Director of
the CDC. 69 Its statutory authority is based on the role of the CDC in
preventing communicable diseases.70 Similarly, professional organizations
like the American Congress of Obstetricians and Gynecologists ("ACOG")
develop immunization recommendations for practitioners." The FDA
effectively allows these recommendations to substitute for regulatory review
specific to pregnant women.72
In 2008, ACIP issued Guiding Principles in Development of ACIP
Recommendations for Vaccination during Pregnancy and Breastfeeding. 73
Previously, the ACIP did not provide any guidance to its constituent
workgroups to formulate policy for vaccination use during pregnancy.7 4
These workgroups took differing approaches to maternal immunization
issues, which resulted in a diverse number of recommendations that "var[ied]
in clarity and underlying rationale."7 5 Since 2004, both ACIP and ACOG
have recommended yearly vaccinations for all women who are pregnant or
planning to become pregnant during the influenza season, regardless of the
mother's age. 7 6 Tdap is also recommended, even though neither is licensed
for use during pregnancy. It is through this system that a fairly small
number of vaccinations have been generally accepted for use during
pregnancy.
68. 42 U.S.C. § 217a; see also CTRS. FOR DISEASE CONTROL & PREVENTION, ABOUT ACIP,
www.cdc.gov/vaccines/acip/about.htmil (last updated Aug. 16, 2012).
69. See CTRS. FOR DISEASE CONTROL & PREVENTION, ACIP CHARTER,
https://www.cdc.gov/vaccines/acip/comiittee/charter.html (last updated Apr. 20, 2016).
70. Id.
71. Id.
72. See, e.g., U.S. FOOD & DRUG AMIN., CLINICAL DEVELOPMENT & REQUIREMENTS FOR
LICENSURE OF VACCINES INTENDED FOR USE DURING PREGNANCY TO PREVENT DISEASE IN THE
INFANT (2015),
www.fda.gov/downloads/AdvisoryComnittees/ComnitteesMeetingMaterials/BloodVaccine
sandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryComniittee/UCM47 166
1.pdf.
73. See CTRS. FOR DISEASE CONTROL & PREVENTION, ACIP: GUIDANCE FOR VACCINE
RECOMMENDATIONS FOR PREGNANT WOMEN,
http://www.cdc.gov/vaccines/acip/conmmittee/guidance/rec-vac-preg.html.
74. Id.
75. Id.
76. See Geeta K. Swamy & R. Phillips Heine, Vaccinations for Pregnant Women, 125
OBSTETRICS & GYNECOLOGY 1,4 (2015).
77. See CTRS. FOR DISEASE CONTROL & PREVENTION, MATERNAL VACCINES: PART OF A
HEALTHY PREGNANCY, http://www.cdc.gov/vaccines/pregnancy/pregnant-women/index.html
(recommending use of tetanus toxiod, reduced diphtheria toxoid and acellular pertussis
vaccine (Tdap) in pregnant women).
28 Vol. 26
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Vaccinations during pregnancy are generally recommended because
pregnant women are at high risk for the most adverse effects of many
vaccine-preventable diseases. 7 Immunization during pregnancy provides
maternal benefit and may have the added benefit of infant protection through
passive immunity.79 Children under the age of 2 months may not be able to
receive a particular vaccine, which means they are dependent upon antibodies
received from their mothers.so
Under this system, it is the phase IV surveillance studies that are
particularly attentive to rare reactions, increases in known reactions, and
signals for risks to pregnant women or their unborn children." The Vaccine
Adverse Event Reporting System ("VAERS") is a safety surveillance project
administered by the CDC and the FDA.82 VAERS collects information about
adverse events associated with the administration of vaccines.83 VAERS
provides a mechanism by which adverse events following immunization may
be reported, analyzed, and made available to the public." Providers must
report adverse events for specific routine childhood immunizations, and are
under professional obligations to report other health events." Patients and
other caregivers also submit reports through the system, which receives up to
30,000 reports per year." Through VAERS, researchers detect new or rare
events, increases in rates of known side effects, and enhance understanding
of patient risk factors. 7 VAERS can facilitate studies analyzing the
association, if any, between vaccination of pregnant women, and pregnancy
outcomes.8
The Vaccine Safety Datalink ("VSD") is another CDC immunization
safety analysis project that partners with nine health care organizations.89
Since 1990, the VSD has monitored the safety of vaccines and undertaken
78. Id.
79. Id.
80. See U.S. DEP'T HEALTH & HUMAN SERVS., RECOMMENDED IMMUNIZATION SCHEDULE
FOR PERSONS AGED 0 THROUGH 18 YEARS,
https://www.vaccines.gov/whoandwhen/infantstoteens/ (last updated Feb. 1, 2016).
81. See U.S. NAT'L LIBRARY OF MED., supra note 47.
82. U.S. DEP'T HEALTH & HUMAN SERVS., ABOUT THE VAERS PROGRAM,
https://vaers.hhs.gov/about/index (last visited Apr. 17, 2016).
83. Id.
84. Id.
85. Id.
86. Id.
87. Id.
88. See, e.g., GS Goldman, Comparison of VAERS Fetal-Loss Reports during Three
Consecutive Influenza Seasons, 32(5) HUM. & EXPERIMENTAL TOXICOLOGY 464, 464 (2013).
89. CTRS. FOR DISEASE CONTROL & PREVENTION, VACCINE SAFETY DATALINK (VSD),
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vsd/ (last updated May 13,
2016).
2017 29
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analyses of associations between immunizations and vaccine side effects.90
The VSD uses electronic health data from partner organizations including the
type of vaccine administered, the date of immunization, and other vaccines
administered on the same day.9 1 The VSD gathers information on illnesses
diagnosed at providers' offices, urgent care and emergency room visits, and
hospital stays.92 The VSD uses this information to develop vaccine safety
studies as well as studies based on questions or concerns raised from the
medical literature and reports to the VAERS.9
The project prioritizes studies evaluating the safety of vaccines given to
women during pregnancy.94 When new vaccines are recommended for use
in the United States or if there are changes in vaccine recommendation (as
there was for Tdap for pregnant women in 2013), the VSD monitors the
safety of these vaccines and recommendations.9 5 Because VSD has nine
databases and retains information regarding up to 2 percent of the United
States' population, VSD enables performance of active surveillance by using
data mining processes.96
Results from VAERS and VDS are also linked with larger databases like
the CDC's Clinical Immunization Safety Assessment Network ("CISA").97
CISA is a resource for healthcare providers who may have safety questions
with respect to certain patients.98 CISA combines expertise in neurology,
allergy, immunology, pediatrics, hematology, and obstetrics/gynecology to
design research studies assessing influenza vaccine safety, vaccine safety in
persons with autoimmune diseases, and vaccine safety in pregnant women. 9 9
Most relevantly for the changes proposed in this article, CISA studies are
designed to address clinical vaccine safety questions in targeted or special
populations that are often excluded from pre-licensure clinical trials, like
pregnant women. 00
IV. BRIDGING THE GAP BETWEEN REGULATORY PATHWAYS FOR
90. Id.
91. Id.
92. Id.
93. Id.
94. Id.
95. Id.
96. Id.
97. CTRS. FOR DISEASE CONTROL & PREVENTION, CLINICAL IMMUNIZATION SAFETY
ASSESSMENT (CISA) PROJECT,
https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/ (last updated Aug. 28,
2015).
98. Id.
99. Id.
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Zika and the Regulatory Regime
VACCINES INTENDED FOR USE DURING PREGNANCY
The regulatory alternative in place - exclusion of pregnant women from
pre-licensure processes, with heavy investments in post-licensure
surveillance and expert recommendations - has produced a short list of
vaccines recommended for all women during pregnancy. Other vaccines are
recommended for women before they become pregnant while others are
recommended under certain circumstances like travel to locations with higher
risk of food-borne illness. But recent public health emergencies - HIN1,
Ebola, and Zika - as well as infections for which vaccination during
pregnancy offers substantial promise show that the current system operates
too slowly and with inadequate regard for the potential of vaccines intended
for use during pregnancy to improve individual and public health.
For example, the current system distorts the development of an ethical
framework for research that might benefit pregnant women and their unborn
children. Under the law, the question is not whether to enroll pregnant
women in clinical trials, but rather how to do so in an "ethically acceptable
and scientifically rigorous manner."ioi Because pregnant women are
reflexively excluded, institutional review boards categorize research in
pregnancies as high risk without undertaking more nuanced assessment of
risks and benefits.1 02
Similar problems occur with respect to baseline rates of certain adverse
events that effect women during pregnancy, an effective calculation of
risk/benefit analysis with respect to research that might be done, and the
language that should accompany product labeling to effectively convey that
risk benefit analysis. While the changes to the PLLR described in Part
III.A.3. are a step in the right direction, manufacturers should still seek
guidance from the FDA on what product narrative will effectively inform
providers and their patients about vaccine risks.
V. CONCLUSION
Recent public health emergencies, especially Zika, have brought into
sharp focus many of the weaknesses of the current system for immunizing
pregnant women. This article has endeavored to trace the pathway for
approval that would typically be used for other medical therapies and
biologic products (including vaccines) and the pathway that is actually used,
which depends upon the historical exclusion of pregnant women from
medical research and long-term experience and expert recommendations
instead of blinded, placebo-controlled trials. Given the threats that influenza,
Ebola, and Zika pose to pregnant women and their unborn children, there is
101. Omer & Beigi, supra note 32.
102. Id.
20 17 3 1
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a compelling justification for making stronger financial and regulatory
investments in rationalizing the process by which vaccines intended for use
during pregnancy are developed and approved.
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